MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer

Peter Olson, Jun Lu, Hao Zhang, Anny Shai, Matthew G. Chun, Yucheng Wang, Steven Libutti, Eric K. Nakakura, Todd R. Golub, Douglas Hanahan

Research output: Contribution to journalArticle

211 Citations (Scopus)

Abstract

While altered expression of microRNAs (miRs) in tumors has been well documented, it remains unclear how the miR transcriptome intersects neoplastic progression. By profiling the miR transcriptome we identified miR expression signatures associated with steps in tumorigenesis and the acquisition of hallmark capabilities in a prototypical mouse model of cancer. Metastases and a rare subset of primary tumors shared a distinct miR signature, implicating a discrete lineage for metastatic tumors. The miR-200 family is strongly down-regulated in metastases and met-like primary tumors, thereby relieving repression of the mesenchymal transcription factor Zeb1, which in turn suppresses E-cadherin. Treatment with a clinically approved angiogenesis inhibitor normalized angiogenic signature miRs in primary tumors, while altering expression of metastatic signature miRs similarly to liver metastases, suggesting their involvement in adaptive resistance to anti-angiogenic therapy via enhanced metastasis. Many of the miR changes associated with specific stages and hallmark capabilities in the mouse model are similarly altered in human tumors, including cognate pancreatic neuroendocrine tumors, implying a generality.

Original languageEnglish (US)
Pages (from-to)2152-2165
Number of pages14
JournalGenes and Development
Volume23
Issue number18
DOIs
StatePublished - Sep 15 2009
Externally publishedYes

Fingerprint

MicroRNAs
Carcinogenesis
Neoplasms
Neoplasm Metastasis
Angiogenesis Inhibitors
Neuroendocrine Tumors
Gene Expression Profiling
Cadherins
Transcriptome
Liver

All Science Journal Classification (ASJC) codes

  • Genetics
  • Developmental Biology

Cite this

Olson, P., Lu, J., Zhang, H., Shai, A., Chun, M. G., Wang, Y., ... Hanahan, D. (2009). MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes and Development, 23(18), 2152-2165. https://doi.org/10.1101/gad.1820109
Olson, Peter ; Lu, Jun ; Zhang, Hao ; Shai, Anny ; Chun, Matthew G. ; Wang, Yucheng ; Libutti, Steven ; Nakakura, Eric K. ; Golub, Todd R. ; Hanahan, Douglas. / MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. In: Genes and Development. 2009 ; Vol. 23, No. 18. pp. 2152-2165.
@article{5874f3a1d299446bb3bf088063b3830a,
title = "MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer",
abstract = "While altered expression of microRNAs (miRs) in tumors has been well documented, it remains unclear how the miR transcriptome intersects neoplastic progression. By profiling the miR transcriptome we identified miR expression signatures associated with steps in tumorigenesis and the acquisition of hallmark capabilities in a prototypical mouse model of cancer. Metastases and a rare subset of primary tumors shared a distinct miR signature, implicating a discrete lineage for metastatic tumors. The miR-200 family is strongly down-regulated in metastases and met-like primary tumors, thereby relieving repression of the mesenchymal transcription factor Zeb1, which in turn suppresses E-cadherin. Treatment with a clinically approved angiogenesis inhibitor normalized angiogenic signature miRs in primary tumors, while altering expression of metastatic signature miRs similarly to liver metastases, suggesting their involvement in adaptive resistance to anti-angiogenic therapy via enhanced metastasis. Many of the miR changes associated with specific stages and hallmark capabilities in the mouse model are similarly altered in human tumors, including cognate pancreatic neuroendocrine tumors, implying a generality.",
author = "Peter Olson and Jun Lu and Hao Zhang and Anny Shai and Chun, {Matthew G.} and Yucheng Wang and Steven Libutti and Nakakura, {Eric K.} and Golub, {Todd R.} and Douglas Hanahan",
year = "2009",
month = "9",
day = "15",
doi = "10.1101/gad.1820109",
language = "English (US)",
volume = "23",
pages = "2152--2165",
journal = "Genes and Development",
issn = "0890-9369",
publisher = "Cold Spring Harbor Laboratory Press",
number = "18",

}

Olson, P, Lu, J, Zhang, H, Shai, A, Chun, MG, Wang, Y, Libutti, S, Nakakura, EK, Golub, TR & Hanahan, D 2009, 'MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer', Genes and Development, vol. 23, no. 18, pp. 2152-2165. https://doi.org/10.1101/gad.1820109

MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. / Olson, Peter; Lu, Jun; Zhang, Hao; Shai, Anny; Chun, Matthew G.; Wang, Yucheng; Libutti, Steven; Nakakura, Eric K.; Golub, Todd R.; Hanahan, Douglas.

In: Genes and Development, Vol. 23, No. 18, 15.09.2009, p. 2152-2165.

Research output: Contribution to journalArticle

TY - JOUR

T1 - MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer

AU - Olson, Peter

AU - Lu, Jun

AU - Zhang, Hao

AU - Shai, Anny

AU - Chun, Matthew G.

AU - Wang, Yucheng

AU - Libutti, Steven

AU - Nakakura, Eric K.

AU - Golub, Todd R.

AU - Hanahan, Douglas

PY - 2009/9/15

Y1 - 2009/9/15

N2 - While altered expression of microRNAs (miRs) in tumors has been well documented, it remains unclear how the miR transcriptome intersects neoplastic progression. By profiling the miR transcriptome we identified miR expression signatures associated with steps in tumorigenesis and the acquisition of hallmark capabilities in a prototypical mouse model of cancer. Metastases and a rare subset of primary tumors shared a distinct miR signature, implicating a discrete lineage for metastatic tumors. The miR-200 family is strongly down-regulated in metastases and met-like primary tumors, thereby relieving repression of the mesenchymal transcription factor Zeb1, which in turn suppresses E-cadherin. Treatment with a clinically approved angiogenesis inhibitor normalized angiogenic signature miRs in primary tumors, while altering expression of metastatic signature miRs similarly to liver metastases, suggesting their involvement in adaptive resistance to anti-angiogenic therapy via enhanced metastasis. Many of the miR changes associated with specific stages and hallmark capabilities in the mouse model are similarly altered in human tumors, including cognate pancreatic neuroendocrine tumors, implying a generality.

AB - While altered expression of microRNAs (miRs) in tumors has been well documented, it remains unclear how the miR transcriptome intersects neoplastic progression. By profiling the miR transcriptome we identified miR expression signatures associated with steps in tumorigenesis and the acquisition of hallmark capabilities in a prototypical mouse model of cancer. Metastases and a rare subset of primary tumors shared a distinct miR signature, implicating a discrete lineage for metastatic tumors. The miR-200 family is strongly down-regulated in metastases and met-like primary tumors, thereby relieving repression of the mesenchymal transcription factor Zeb1, which in turn suppresses E-cadherin. Treatment with a clinically approved angiogenesis inhibitor normalized angiogenic signature miRs in primary tumors, while altering expression of metastatic signature miRs similarly to liver metastases, suggesting their involvement in adaptive resistance to anti-angiogenic therapy via enhanced metastasis. Many of the miR changes associated with specific stages and hallmark capabilities in the mouse model are similarly altered in human tumors, including cognate pancreatic neuroendocrine tumors, implying a generality.

UR - http://www.scopus.com/inward/record.url?scp=70349145414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349145414&partnerID=8YFLogxK

U2 - 10.1101/gad.1820109

DO - 10.1101/gad.1820109

M3 - Article

VL - 23

SP - 2152

EP - 2165

JO - Genes and Development

JF - Genes and Development

SN - 0890-9369

IS - 18

ER -